Clinical Trial Update: Effects of Docosahexanoic Acid on Neurocognitive Impairment in HIV-infected Patients [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on docosahexaenoic acid (DHA) for neurocognitive impairment in HIV-infected patients (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Neurocognitive Impairment

Drugs mentioned

• Docosahexaenoic acid (docosahexaenoic acid)

Snippet

Sponsor: Fudan University | Conditions: Neurocognitive Impairment | Phase 1, Phase 2 | Status: UNKNOWN